They had a few investors for the drugs that did not statistically respond past the phase II studies, thus those investors sold. As a company they have reogranized and are moving forward with two new candidates, one of which starts dosing Sept. 2015. The other is in pre-trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.